Krishnendu Roy

Krishnendu Roy

Auto-generated profile, based on publicly available information

Krishnendu Roy

Department of Biomedical Engineering, School of Engineering, Vanderbilt University, Nashville, Tennessee, USA; Department of Pathology, Microbiology and Immunology, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA; Department of Chemical and Biomolecular Engineering, School of Engineering, Vanderbilt University, Nashville, Tennessee, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RARachit Agarwal
Rachit Agarwal
VSVikramjit Singh
Vikramjit Singh
PJPatrick Jurney
Patrick Jurney
LSLi Shi
Li Shi
SSS. V. Sreenivasan
S. V. Sreenivasan
KRKrishnendu Roy
Krishnendu Roy
Significance: Nanoparticles are widely investigated for intracellular drug delivery and molecular imaging and should be designed to maximize cell uptake. Here the effects of particle geometry to maximize nanoparticle uptake by mammalian cells are evaluated. The findings show that uptake is governed by a combination of cell–particle adhesion, strain energy for membrane wrapping around the particle, and local particle concentration at the cell membrane, all of which are particle-shape–dependent. Under typical culture conditions, disc-shaped hydrophilic nanoparticles were internalized more efficiently than nanorods. Interestingly, larger nanodiscs and rods had higher uptake compared with the smallest particles tested. Mechanisms of uptake were also shape- and cell type-specific. These results provide important insights for rational design of nanocarriers to maximize intracellular delivery efficacy.

16 September 2015 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
RARachit Agarwal
Rachit Agarwal
PJPatrick Jurney
Patrick Jurney
MRMansi Raythatha
Mansi Raythatha
VSVikramjit Singh
Vikramjit Singh
SSSidlgata. V. Sreenivasan
Sidlgata. V. Sreenivasan
KRKrishnendu Roy
Krishnendu Roy

1 March 2016 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
RTRandall Toy
Randall Toy
KRKrishnendu Roy
Krishnendu Roy
Advances in immunotherapy have led to the development of a variety of promising therapeutics, including small molecules, proteins and peptides, monoclonal antibodies, and cellular therapies. Despite this wealth of new therapeutics, the efficacy of immunotherapy has been limited by challenges in targeted delivery and controlled release, that is, spatial and temporal control on delivery. Particulate carriers, especially nanoparticles have been widely studied in drug delivery and vaccine research and are being increasingly investigated as vehicles to deliver immunotherapies. Nanoparticle‐mediated drug delivery could provide several benefits, including control of biodistribution and transport kinetics, the potential for site‐specific targeting, immunogenicity, tracking capability using medical imaging, and multitherapeutic loading. There are also a unique set of challenges, which include nonspecific uptake by phagocytic cells, off‐target biodistribution, permeation through tissue (transport limitation), nonspecific immune‐activation, and poor control over intracellular localization. This review highlights the importance of understanding the relationship between a nanoparticle's size, shape, charge, ligand density and elasticity to its vascular transport, biodistribution, cellular internalization, and immunogenicity. For the design of an effective immunotherapy, we highlight the importance of selecting a nanoparticle's physical characteristics (e.g., size, shape, elasticity) and its surface functionalization (e.g., chemical or polymer modifications, targeting or tissue‐penetrating peptides) with consideration of its reactivity to the targeted microenvironment (e.g., targeted cell types, use of stimuli‐sensitive biomaterials, immunogenicity). Applications of this rational nanoparticle design process in vaccine development and cancer immunotherapy are discussed.

26 August 2020 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
JMJoscelyn C. Mejías
Joscelyn C. Mejías
MNMichael R. Nelson
Michael R. Nelson
OLOlivia Liseth
Olivia Liseth
KRKrishnendu Roy
Krishnendu Roy
Development of organoids and microfluidic on-chip models has enabled studies of organ-level disease pathophysiologies in vitro. However, current lung-on-a-chip platforms are primarily monolayer epithelial–endothelial co-cultures, separated by a thin membrane, lacking microvasculature-networks or interstitial-fibroblasts. Here we report the design, microfabrication, and characterization of a unique microphysiological on-chip device that recapitulates the human lung interstitium–airway interface through a 3D vascular network, and normal or diseased fibroblasts encapsulated within a fibrin-collagen hydrogel underneath an airlifted airway epithelium. By incorporating fibroblasts from donors with idiopathic pulmonary fibrosis (IPF), or healthy-donor fibroblasts treated with TGF-β1, we successfully created a fibrotic, alpha smooth muscle actin (αSMA)-positive disease phenotype which led to fibrosis-like transformation in club cells and ciliated cells in the airway. Using this device platform, we further modeled the cystic fibrosis (CF) epithelium and recruitment of neutrophils to the vascular networks. Our results suggest that this microphysiological model of the human lung could enable more pathophysiologically relevant studies of complex pulmonary diseases.

1 July 2014 in Biomaterials
Verified
Journal Article
Closed access
PPPallab Pradhan
Pallab Pradhan
HQHong Qin
Hong Qin
JLJardin A. Leleux
Jardin A. Leleux
DGDongho Gwak
Dongho Gwak
ISIppei Sakamaki
Ippei Sakamaki
KRKrishnendu Roy
Krishnendu Roy

1 March 2021 in Biomaterials
Verified
Journal Article
Closed access
MNMichael R. Nelson
Michael R. Nelson
DGDelta Ghoshal
Delta Ghoshal
JMJoscelyn C. Mejías
Joscelyn C. Mejías
DRDavid Frey Rubio
David Frey Rubio
EKEmily Keith
Emily Keith
KRKrishnendu Roy
Krishnendu Roy